Home > Healthcare > Biotechnology > Biotechnology R&D > Aptamers Market
Aptamers Market size accounted for USD 2.9 billion in 2023 and is estimated to grow at 20.3% to reach USD 15.1 billion by 2032. Distinct advantages that aptamers offer over traditional antibodies are driving the rapid development of the industry.
Aptamers, with their unique characteristics of high specificity and affinity for target molecules, are poised to revolutionize various industries, particularly in healthcare and biotechnology. Also, unlike antibodies, aptamers can be easily synthesized and chemically modified, enabling swift optimization for specific applications. This scalability ensures efficient and cost-effective production, expediting research and development processes. Moreover, aptamers' small size, low immunogenicity, and ease of customization result in enhanced target binding and reduced off-target effects.
Aptamers are short, single-stranded DNA, RNA, or peptide molecules that are selected from large libraries of random sequences through a process known as systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have a unique three-dimensional structure that allows them to specifically bind to target molecules, such as proteins, nucleic acids, small molecules, or cells, with high affinity and selectivity.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Aptamers Market Size in 2023: | USD 2.9 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2024 to 2032 CAGR: | 20% |
2032 Value Projection: | USD 15.1 Billion |
Historical Data for: | 2018 to 2023 |
No. of Pages: | 180 |
Tables, Charts & Figures: | 262 |
Segments covered: | Type, Application, Technology, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|